Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
20.72
-0.28 (-1.33%)
At close: Jan 12, 2026, 4:00 PM EST
20.72
0.00 (0.00%)
After-hours: Jan 12, 2026, 4:35 PM EST
Syndax Pharmaceuticals Employees
Syndax Pharmaceuticals had 270 employees as of December 31, 2024. The number of employees increased by 86 or 46.74% compared to the previous year.
Employees
270
Change (1Y)
86
Growth (1Y)
46.74%
Revenue / Employee
$412,237
Profits / Employee
-$1,153,989
Market Cap
1.80B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 270 | 86 | 46.74% |
| Dec 31, 2023 | 184 | 77 | 71.96% |
| Dec 31, 2022 | 107 | 48 | 81.36% |
| Dec 31, 2021 | 59 | 16 | 37.21% |
| Dec 31, 2020 | 43 | 8 | 22.86% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SNDX News
- 10 hours ago - Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 days ago - Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S. - GlobeNewsWire
- 7 days ago - Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 26 days ago - Syndax Pharma: Continuing Execution In AML - Seeking Alpha
- 4 weeks ago - Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025 - GlobeNewsWire
- 4 weeks ago - Syndax Pharmaceuticals, Inc. (SNDX) Presents at The 67th American Society of Hematology (ASH) Annual Meeting Transcript - Seeking Alpha
- 5 weeks ago - Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum - GlobeNewsWire
- 5 weeks ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire